Biologics for Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Brodalumab Approved for Psoriasis
The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.
Measuring the Value of How a Patient “Feels”
How a patient feels may be a better indicator of the effectiveness of treatment than actual disease activity, researchers say.
35% of PsA Patients Suffer from Clinical Enthesitis
Clinical enthesitis is a common condition for some psoriatic arthritis patients who are disproportionately affected by inflammation, particularly of the Achilles tendon, plantar fascia and lateral epicondyle.
Psoriatic Spondyloarthritis Burden is Similar to Ankylosing Spondylitis
Psoriatic spondyloarthritis forms part of the spondyloarthritis spectrum, between peripheral-only psoriatic arthritis and ankylosing spondylitis.
Psoriasis Patients Require Annual PsA Screening
Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.
Statins with TNFa Treatment Lowers LDL levels in PsA
TNF-α inhibitor treatment in PsA, RA and AS may be associated with a significant increase in total cholesterol, triglycerides and the atherogenic index. Statins with treatment lowered LDL levels.
Obesity's Role in the Treatment and Development of Disease
Obesity was a common theme at RNS16 this year in which speakers touched on obesity as a cause of disease onset and even as one that can prevent therapeutic treatments from working.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
Biologic Switching in PsA: 5 Things Rheumatologists Need to Know
In this slideshow, we highlight five of the top concerns and questions physicians have about switching patients from one biologic to another in psoriatic arthritis.
10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
By clicking Accept, you agree to become a member of the UBM Medica Community.